A recent study reveals that individuals who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt traditional lifestyle regimens.
Research printed in a leading health publication shows that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month after stopping.
"Users purchasing such medications need to be aware of the potential of quick weight regain when the therapy is stopped," warns expert Dr. Susan Jebb.
This pace of regain implies a reversion to original mass in about a year and a half.
Analyzing Therapies
The analysis, which reviewed dozens of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with older methods.
Scientists note that people who shed pounds through diet and exercise typically have a more gradual creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Doctors believe the mode of action of the drugs accounts for the heightened rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone concentrations several times higher than normal may cause the system to produce less of its endogenous GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication results in hunger is uncontrolled, making excessive eating a significant risk."
An Ongoing Issue?
The NHS recommend the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals argue that, considering the high risk of relapse, the therapy might need to be ongoing.
This view is supported by drug manufacturers, who state that the findings "underscore the chronic character of excess weight," akin to managing conditions like hypertension.
User Experiences
Individuals who have stopped the jabs report a intense resurgence of cravings.
"It felt as if a trigger that goes on and you become starving," said one woman.
The struggle is compounded if patients have not developed permanent dietary or behavioural changes during therapy.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have used these injections in the past year, with desire being substantial.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Finally, clinicians emphasize that while these medications are powerful agents for weight loss, they are not a magic fix and maintained weight loss hinges on combined behavioural management.
